IBDEI0YP ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17240,1,8,0)
 ;;=8^Megakaryocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,17240,2)
 ;;=^336483
 ;;^UTILITY(U,$J,358.3,17241,0)
 ;;=207.80^^111^1077^47
 ;;^UTILITY(U,$J,358.3,17241,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17241,1,1,0)
 ;;=1^207.80
 ;;^UTILITY(U,$J,358.3,17241,1,8,0)
 ;;=8^Oth Spec Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,17241,2)
 ;;=^336869
 ;;^UTILITY(U,$J,358.3,17242,0)
 ;;=207.81^^111^1077^46
 ;;^UTILITY(U,$J,358.3,17242,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17242,1,1,0)
 ;;=1^207.81
 ;;^UTILITY(U,$J,358.3,17242,1,8,0)
 ;;=8^Oth Spec Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,17242,2)
 ;;=^267562
 ;;^UTILITY(U,$J,358.3,17243,0)
 ;;=207.82^^111^1077^45
 ;;^UTILITY(U,$J,358.3,17243,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17243,1,1,0)
 ;;=1^207.82
 ;;^UTILITY(U,$J,358.3,17243,1,8,0)
 ;;=8^Oth Spec Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,17243,2)
 ;;=^336484
 ;;^UTILITY(U,$J,358.3,17244,0)
 ;;=208.00^^111^1077^21
 ;;^UTILITY(U,$J,358.3,17244,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17244,1,1,0)
 ;;=1^208.00
 ;;^UTILITY(U,$J,358.3,17244,1,8,0)
 ;;=8^Leukemia Unspec w/o Remission
 ;;^UTILITY(U,$J,358.3,17244,2)
 ;;=^336870
 ;;^UTILITY(U,$J,358.3,17245,0)
 ;;=208.01^^111^1077^20
 ;;^UTILITY(U,$J,358.3,17245,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17245,1,1,0)
 ;;=1^208.01
 ;;^UTILITY(U,$J,358.3,17245,1,8,0)
 ;;=8^Leukemia Unspec in Remission
 ;;^UTILITY(U,$J,358.3,17245,2)
 ;;=^267566
 ;;^UTILITY(U,$J,358.3,17246,0)
 ;;=208.02^^111^1077^19
 ;;^UTILITY(U,$J,358.3,17246,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17246,1,1,0)
 ;;=1^208.02
 ;;^UTILITY(U,$J,358.3,17246,1,8,0)
 ;;=8^Leukemia Unspec in Relapse
 ;;^UTILITY(U,$J,358.3,17246,2)
 ;;=^336485
 ;;^UTILITY(U,$J,358.3,17247,0)
 ;;=208.10^^111^1077^12
 ;;^UTILITY(U,$J,358.3,17247,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17247,1,1,0)
 ;;=1^208.10
 ;;^UTILITY(U,$J,358.3,17247,1,8,0)
 ;;=8^Chr Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,17247,2)
 ;;=^336871
 ;;^UTILITY(U,$J,358.3,17248,0)
 ;;=208.11^^111^1077^11
 ;;^UTILITY(U,$J,358.3,17248,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17248,1,1,0)
 ;;=1^208.11
 ;;^UTILITY(U,$J,358.3,17248,1,8,0)
 ;;=8^Chr Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,17248,2)
 ;;=^267569
 ;;^UTILITY(U,$J,358.3,17249,0)
 ;;=208.12^^111^1077^10
 ;;^UTILITY(U,$J,358.3,17249,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17249,1,1,0)
 ;;=1^208.12
 ;;^UTILITY(U,$J,358.3,17249,1,8,0)
 ;;=8^Chr Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,17249,2)
 ;;=^336486
 ;;^UTILITY(U,$J,358.3,17250,0)
 ;;=208.20^^111^1077^53
 ;;^UTILITY(U,$J,358.3,17250,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17250,1,1,0)
 ;;=1^208.20
 ;;^UTILITY(U,$J,358.3,17250,1,8,0)
 ;;=8^Subacute Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,17250,2)
 ;;=^336872
 ;;^UTILITY(U,$J,358.3,17251,0)
 ;;=208.21^^111^1077^52
 ;;^UTILITY(U,$J,358.3,17251,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17251,1,1,0)
 ;;=1^208.21
 ;;^UTILITY(U,$J,358.3,17251,1,8,0)
 ;;=8^Subacute Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,17251,2)
 ;;=^267572
 ;;^UTILITY(U,$J,358.3,17252,0)
 ;;=208.22^^111^1077^51
 ;;^UTILITY(U,$J,358.3,17252,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17252,1,1,0)
 ;;=1^208.22
 ;;^UTILITY(U,$J,358.3,17252,1,8,0)
 ;;=8^Subacute Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,17252,2)
 ;;=^336487
 ;;^UTILITY(U,$J,358.3,17253,0)
 ;;=208.80^^111^1077^38
 ;;^UTILITY(U,$J,358.3,17253,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17253,1,1,0)
 ;;=1^208.80
 ;;^UTILITY(U,$J,358.3,17253,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
